| gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points R Mu, Y Yuan, J Xu, SJ Mandrekar, J Yin Journal of the Royal Statistical Society Series C: Applied Statistics 68 (2 …, 2019 | 42 | 2019 |
| Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial MC Zhang, S Tian, D Fu, L Wang, S Cheng, HM Yi, XF Jiang, Q Song, ... Cancer Cell 41 (10), 1705-1716. e5, 2023 | 17 | 2023 |
| A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials R Mu, H Pan, G Xu Statistics in Medicine, 2021 | 8 | 2021 |
| Sequential design for response surface model fit in computer experiments using derivative information R Mu, L Dai, J Xu Communications in Statistics-Simulation and Computation 46 (2), 1148-1155, 2017 | 6 | 2017 |
| A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications R Mu, J Xu, R Tang, S Kopetz, Y Yuan Statistics in Medicine 41 (2), 374-389, 2022 | 4 | 2022 |
| A new bayesian dose-finding design for drug combination trials R Mu, J Xu Statistics in Biopharmaceutical Research 9 (4), 384-389, 2017 | 4 | 2017 |
| Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial Q Shi, Y He, HM Yi, RJ Mu, XF Jiang, D Fu, L Dong, W Qin, PP Xu, ... Cancer communications (London, England), 2023 | 3 | 2023 |
| A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials R Mu, G Xu, G Liu, H Pan Contemporary Clinical Trials 108, 106504, 2021 | 2 | 2021 |
| A Bayesian stochastic approximation method J Xu, R Mu, C Xiong Journal of Statistical Planning and Inference 211, 391-401, 2021 | 2 | 2021 |
| A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation J Xu, D Zhang, R Mu BMC Medical Research Methodology 22 (1), 258, 2022 | 1 | 2022 |
| An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials R Mu, Z Hu, G Xu, H Pan BMC Medical Research Methodology 21, 1-12, 2021 | 1 | 2021 |
| A Bayesian adaptive design for biosimilar trials with time‐to‐event endpoint SY Belay, R Mu, J Xu Pharmaceutical Statistics 20 (3), 597-609, 2021 | 1 | 2021 |
| Posterior propriety of an objective prior in a 4-Level normal hierarchical model C Song, D Sun, K Fan, R Mu Mathematical Problems in Engineering 2020, 1-10, 2020 | 1 | 2020 |
| Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma Y Wang, Q Shi, ZY Shi, S Tian, MC Zhang, R Shen, D Fu, L Dong, HM Yi, ... Blood Advances 8 (7), 1587-1599, 2024 | | 2024 |
| Using an inequality constraint to increase the power of the homogeneity tests for a two-sample problem with a mixture structure G Liu, R Mu, Y Liu, Z Sheng Communications in Statistics-Theory and Methods 52 (18), 6475-6486, 2023 | | 2023 |
| An R package for continuous and ordinal outcomes in Phase I dose-finding trials H Pan, R Mu, CW Hsu, S Zhou Communications for Statistical Applications and Methods 29 (4), 421-439, 2022 | | 2022 |
| Testing homogeneity in contaminated mixture models G Liu, Y Fu, W Liu, R Mu* Canadian Journal of Statistics, 2021 | | 2021 |
| Package ‘UnifiedDoseFinding’ CW Hsu, H Pan, R Mu, MCW Hsu | | 2020 |
| Research Article Posterior Propriety of an Objective Prior in a 4-Level Normal Hierarchical Model C Song, D Sun, K Fan, R Mu | | 2020 |
| Predicting events in clinical trials using two time‐to‐event outcomes R Mu, J Xu Biometrical Journal 60 (4), 815-826, 2018 | | 2018 |
Haitao PanSt. Jude Children's Research HospitalVerified email at stjude.org
